Navigation Links
GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg)

said Michael R. Dougherty, President and Chief Executive Officer of Adolor. "We are committed to working with GSK to provide an update on further clinical development plans in the opioid-induced bowel dysfunction program as soon as is possible. With regard to the POI program, we continue to target the second quarter of 2007 to submit to the FDA a Complete Response to the November 2006 approvable letter."

Conference Call Information

Adolor will be hosting a conference call and webcast on April 9, 2007 at 5:00 p.m. Eastern Time 2:00 p.m. Pacific Time to discuss these results. To participate in the audio portion and have the opportunity to pose questions, dial 1-866-383-7989 for domestic callers, and 1-617-597-5328 for international callers, and provide the Passcode 76912495. Slides accompanying the call, as well as a webcast of the audio portion of the call, will be available on the Investor Relations section of the Company's website, www.adolor.com.

A replay of the conference call will be available beginning at 7:00 PM Eastern Time on April 9, 2007. To listen to a replay of the conference call, dial 1-888-286-8010 (domestic callers) or 1-617-801-6888 (international callers) with a Passcode of 78747273 or listen via the website. The replay will be available for one week.

About Adolor Corporation

Adolor Corporation (Nasdaq:ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. Entereg(R) (alvimopan) is Adolor's lead product candidate under development for the management of the gastrointestinal side effects associated with opioid use. Adolor and GlaxoSmithKline (GSK) are collaborating in the worldwide development and commercialization of Entereg(R) in multiple indications. Adolor also has a number of discovery research programs focused on the identification of novel compounds for the treatment of pain. By applying its knowledge and expertise
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/28/2014)... July 28, 2014  ANI Pharmaceuticals, Inc. (NASDAQ: ... to release its second quarter and year-to-date 2014 financial ... of the U.S. financial markets. The earnings press release ... the Company,s website, www.anipharmaceuticals.com . ... and Charlotte C. Arnold , Vice President and ...
(Date:7/28/2014)... 28, 2014  ProteinSimple announced today that it has ... new assay allows users to detect all proteins separated ... Western users can analyze proteins without the need for ... changed protein analysis as we know it today. First, the ... - no messy gels, no transfer tanks, no blots, ...
(Date:7/28/2014)... , July 28, 2014 ... £2.5 million to help it meet the global ... healthcare, pharmaceuticals and logistics. Albion joins Shackleton Ventures. ... Over the past 18 months OmPrompt ... platform, its management team and its operations. The ...
Breaking Medicine Technology:ANI Pharmaceuticals Schedules Conference Call for Second Quarter 2014 Financial Results 2ProteinSimple Says "Never Run a Gel Again!" 2OmPrompt Funded for Customer Automation Management Market Expansion 2
(Date:7/28/2014)... July 28, 2014 Humility of Mary Health ... 20 at St. Elizabeth Boardman Health Center, 8401 Market St., ... provides information about more than 200 common health problems as ... preventing illness and injury, and advice on when to seek ... a.m. to noon, the evening session runs from 5:30 to ...
(Date:7/28/2014)... 2014 For those with dust allergies, home ... dust allergies—commonly settle in mattresses, bedding, and upholstered furniture and ... mites are microscopic insects that feed on the dead skin ... to keep a million dust mites fat and happy. When ... microscope, the decaying bodies and feces of dust mites can ...
(Date:7/28/2014)... July 28, 2014 Scientists in Japan ... an improved blood test for the asbestos cancer mesothelioma. ... new research. Click here to read it now. ... at Tokyo’s Juntendo University Graduate School of Medicine say ... is a step above the old test. , ...
(Date:7/28/2014)... 2014 Maternal and Family Health Services ... which will be presented at the agency’s 43rd Annual ... at the Westmoreland Club in Wilkes-Barre. , The late ... long-time employee of MFHS. She dedicated her life ... health advocate, and champion for women, children and families ...
(Date:7/28/2014)... new study has found that following a healthy lifestyle ... metabolic syndrome. Published early online in CANCER , ... findings indicate that children with cancer and adults who ... about how their lifestyle may influence their long-term health. ... known to be at increased risk for the metabolic ...
Breaking Medicine News(10 mins):Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 2Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 3Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:MFHS Seeking Nominations for Rose Allan Tucker Award 2Health News:Lifestyle choices may affect the long-term heart health of childhood cancer survivors 2
... Pa., Jan. 15 Today marked the launch ... http://www.nabita.org ). NaBITA,s mission: The National Behavioral ... education, development and support to professionals in schools ... to make their campuses and workplaces safer through ...
... 15 Eli Lilly and Company,(NYSE: ... resolution with the United,States Attorney for the Eastern ... Litigation of the Department of Justice regarding the,previously-reported ... promotional practices for the antipsychotic medication,Zyprexa(R) (olanzapine). , ...
... of the revolutionary MyFluVaccine program launches new website as it ... ... (Vocus) January 15, 2009 -- FFF Enterprises, the nation’s largest ... critical-care biopharmaceuticals announced today the unveiling of its new and ...
... Valley Hospital chooses IVANS LIME, impressed with quick turnaround time and ... ... 15, 2009 -- IVANS , the leading provider of corporate ... choosing high-speed Internet technology over dial-up to access Medicare as they ...
... January 15 Essilor,International announced today that its ... share purchase agreement whereby it has offered to ... of ophthalmic lenses. The,agreement is subject to certain ... Signet Armorlite,s main host,countries. The acquisition is expected ...
... great friend to The Brain Tumor Foundation lost his battle ... surrounded by his family.David fought his illness with courage and ... website, 38lemon.com , he shared his personal battle and ... cancer. So named because of his diagnosis of a ...
Cached Medicine News:Health News:Preventing the Next Virginia Tech -- The National Behavioral Intervention Team Association Launched Today 2Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 2Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 3Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 4Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 5Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 6Health News:Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 7Health News:FFF Enterprises Launches New MyFluVaccine Website 2Health News:FFF Enterprises Launches New MyFluVaccine Website 3Health News:Healthcare Providers Choosing IVANS High-Speed Technology to Succeed Within Medicare Modernization Era 2Health News:Healthcare Providers Choosing IVANS High-Speed Technology to Succeed Within Medicare Modernization Era 3Health News:Essilor Agrees to Acquire Signet Armorlite 2
To enter, dissect, elevate and smooth the flap. Combined features of Spatula, Dissector and Forceps. - Also available in Titanium...
Khosla Precision and Quality in Medical and Surgical Products....
The Retina 145 L direct contact glass is a panfundus wide-angle viewing device designed to facilitate the problem-free diagnosis and treatment of the retina as far as the equator....
For children up to 4 years of age 11 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
Medicine Products: